Bio Path Holdings Inc (BPTH)

[SJSTOCKSHARK]

Dr. Hayne has direct experience with AML but it was not favorable. Vion's drug "Onrigin was rejected by the Food and Drug Administration for an AML indication in 2009 due to an unfavorable risk-benefit profile, the company became defunct."

https://en.wikipedia.org/wiki/Vion_Pharmaceuticals,_Inc.

Perhaps he is excited about the lack of toxicity shown by PREXIGEBERSON. He experienced a failure as Vion went bankrupt in 2009 so we hope he learned from this experience.

This do not solve our problem. We need a new CEO.

Here is what VION said when they hired Dr. Hahne in 2008.

"NEW HAVEN, Conn., Feb. 4 /PRNewswire-FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that William Hahne, M.D. has joined the Company's senior management team as Vice President,Medical.

Alan Kessman, Chief Executive Officer, said, "We are extremely pleased to have Bill Hahne joining Vion in medical affairs. He has a wealth of experience in clinical development which will be extremely useful to our efforts to file a New Drug Application for Cloretazine(R) (VNP40101M) with the U.S. Food and Drug Administration in 2008."

Dr. Hahne commented, "Based on the data from two Phase II trials in elderly patients with previously untreated AML, Cloretazine(R) (VNP40101M)is an active agent in this indication. I am looking forward to working with the rest of Vion's senior management team to pursue regulatory approval for Cloretazine(R) (VNP40101M) in the United States."

Prior to joining Vion, Dr. Hahne, 54, was Vice President, Clinical
Development, and then Vice President of Clinical Development and Medical Affairs of Celsion Corporation from January 2006 to December 2007. From 2003 to 2005, Dr. Hahne was Vice President of Clinical Development for CuraGen Corporation. From 1986 to 2002, Dr. Hahne worked in various positions in medical affairs for Glaxo Inc., Merrell Dow Research Institute, Marion Merrell Dow, Hoechst Marion Rousel, and Eisai, Inc. Dr. Hahne received his medical degree from Cornell University Medical College and conducted his residency in general surgery at Emory University
Affiliated Hospitals in Atlanta, Georgia.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia."